FDA ER-LA REMS Day One of Meeting of the Drug Safety and Risk Management Advisory Committee
Discussion ensued as to whether the rate of success is translating into improved outcomes. The discussion seemed as though it was positive for CE and REMS, and that some industry leaders recognize that working with CE providers to help educate providers is beneficial to patients and the healthcare system overall.
The meeting continues Wednesday, May 4, 2016, with discussions that are expected to elicit recommendations from the panel members.
Related StoriesCME and the Opioid CrisisFDA Opinion on Proactive Response to Prescription Opioid AbuseThe FDA Shield - The Medtronic Infuse Case and the Latest Tango of Preemption Versus Liability
Source: Policy and Medicine - Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
More News: Anesthesia | Anesthesiology | Budgets | Education | Epidemics | Epidemiology | Food and Drug Administration (FDA) | Health | Health Medicine & Bioethics Commentators | Medicaid | National Institutes of Health (NIH) | Pharmaceuticals | Rural Health | Statistics | Substance Abuse | Training | Universities & Medical Training